Alnylam Pharmaceuticals, Inc.
(Nasdaq:ALNY), a leading RNAi therapeutics company, today announced that
it has initiated a Phase 1/2 clinical trial with ALN-CC5, a
subcutaneously administered investigational RNAi therapeutic targeting
complement component C5 for the treatment of complement-mediated
for Alnylam Initiates Phase 1/2 Clinical Trial for ALN-CC5, a Subcutaneously Administered RNAi Therapeutic Targeting Complement Component C5 in Development for the Treatment of Complement-Mediated Diseases investment picks